Several Midwestern Cities have been designated as HIV “hotspots” due to the rising number of new cases; and the South ...

Millions of lives and decades of progress hang in the balance,” says the president of the International AIDS Society (IAS) ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Countries in sub-Saharan Africa could see thousands of deaths from HIV due to cuts to the US President’s Emergency Plan for AIDS Relief (PEPFAR), underscoring the necessity of reinstating the program.

Major setbacks in the global fight against HIV may be imminent due to recent funding cuts, public health experts have warned ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse ...

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...

Today, Pride is still an uprising. Keeping HIV awareness and prevention at the heart of Pride Month deepens its mission and ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

A religious movement that has so often taken public stands has been unusually quiet since Trump gutted the program to combat ...